LKT Laboratories, Inc.

Irinotecan Hydrochloride Trihydrate

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID I6933
CAS No. 136572-09-3
Chemical Name [1,4'-Bipiperidine]-1'-carboxylic acid (4S)-4,11- diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo- 1H-pyrano[3',4':6,7]indolizino[1,2-b] quinolin-9-yl ester hydrochloride trihydrate
Synonym Irinotecan hydrochloride trihydrate, Camptosar, Campto, CPT -11



Formula $C_{33}H_{38}N_4O_6 \cdot HCl \cdot 3H_2O$
Formula Wt. 677.19
Melting Point 256.5°C
Purity ≥98%
Solubility Slightly soluble in water (25 mg/mL), ethanol (7 mg/mL), chloroform. DMSO (100 mg/mL)
Store Temp 4°C
Ship Temp Ambient

Bulk quanitites available upon request

Product ID	Size
I6933	5 mg
I6933	10 mg
I6933	25 mg
I6933	100 mg

Description Irinotecan is an analog of camptothecin that is used clinically to treat colon and ovarian cancers, among others. Irinotecan exhibits anticancer chemotherapeutic, anti-angiogenic, and immunosuppressive activities. Irinotecan inhibits DNA topoisomerase I and sensitizes tumors to the effects of radiation. In glioma models, irinotecan decreases the number of tumor vessels and decreases expression of VEGF and HIF-1α, inhibiting tumor growth. Irinotecan also moderates inhibition of dendritic cell differentiation and may produce cholinergic side effects, suggesting potential inhibition of acetylcholinesterase (AChE) as well.

References

Hu J, Kinn J, Zirakzadeh AA, et al. The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clin Exp Immunol. 2013 Jun;172(3):490-9. PMID: 23600838.

Pan P, Li Y, Yu H, et al. Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches. J Chem Inf Model. 2013 Apr 22;53(4):997-1006. PMID: 23521602.

Chen AY, Chen PM, Chen YJ. DNA topoisomerase I drugs and radiotherapy for lung cancer. J Thorac Dis. 2012 Aug;4(4):390-7. PMID: 22934142.

Chintala S, Tóth K, Cao S, et al. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha. Cancer Chemother Pharmacol. 2010 Oct;66(5):899-911. PMID: 20066420.

Dodds HM, Rivory LP. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Mol Pharmacol. 1999 Dec;56(6):1346-53. PMID: 10570064.